Kornimate/medical-research-clean huggingface dataset:
sagittal spinopelvic parameters in patients with lower extremity amputation

Conditions: Amputation, Traumatic; Low Back Pain

Summary: the aim of this study is to investigate the relationship between sagittal spinopelvic parameters and low back pain and quality of life in individuals with lower extremity amputation.

low back pain is one of the secondary health problems that negatively affect functionality, independence and quality of life in individuals with lower extremity amputation. the prevalence of low back pain was reported to be higher in individuals with lower extremity amputation (52-89%) than in the non-amputee population (12-45%). although the etiology of low back pain is multifactorial, changing anatomy and biomechanics after lower extremity amputation and maintaining daily activities are often associated with the development of low back pain. postural imbalance, which is one of the musculoskeletal disorders of the spine that contributes to low back pain, is considered to cause additional load on the spinal structures.

Eligibility criteria:
inclusion criteria: * patients aged ≥ 18 and ≤ 65 years * patients followed for at least 12 months with lower extremity amputation * patients who have been using prosthesis for at least 3 months * patients with stable medical and psychological status * patients willing to participate in the study exclusion criteria: * patients with serious cardiovascular, pulmonary, neurological disease or other musculoskeletal problems (inflammatory rheumatic disease, active synovitis, severe low back pain, hip/knee joint replacement or other hip/knee-related trauma, fracture, or surgery) that impair walking * patients with severe vision, hearing and language problems
standard versus comprehensive care for post acute kidney injury

Conditions: Acute Kidney Injury

Summary: the investigators aim to compare between standard versus comprehensive care for post-acute kidney injury who are admitted with acute kidney injury at least stage 2 or receive renal replacement therapy.


Eligibility criteria:
inclusion criteria: * acute kidney injury at least stage 2 or * received renal replacement therapy exclusion criteria: * post kidney transplantation * end-stage renal disease
periodontal disease and salivary mitofusin levels

Conditions: Periodontitis; Periodontal Diseases; Gingivitis

Summary: the aim of this observational study is to find out whether there is a level difference in salivary mitofusin-1 and mitofusin-2 levels due to changes in periodontal status. the main question it aims to answer is: * do salivary mitofusin-1 and mitofusin-2 levels of periodontitis patients differ from healthy patients? * could salivary mitofusin-1 and mitofusin-2 levels be biomarkers for periodontal disease? biochemical analysis will be performed on saliva samples taken at once from gingivitis or periodontitis patients and healthy individuals who apply to the periodontology clinic, at the initial stage of the treatment. there is no ongoing monitoring or second sampling.


Eligibility criteria:
inclusion criteria: * being between the ages of 18 and 65. * willing to participate in the study and provide a saliva sample. * having a healthy periodontal condition, gingivitis, or periodontitis (stage 3-4, grade c). * having fasted from any food or drink (except water) for the past 2 hours prior to providing the saliva sample. * having refrained from brushing teeth or using mouthwash in the past 2 hours prior to providing the saliva sample. * not having any systemic diseases. * not currently taking any medications regularly. exclusion criteria: * having used antibiotics within the last 6 months. * having received periodontal treatment within the last 6 months. * having fewer than 20 teeth (excluding third molars). * having any systemic diseases. * not smoking or having quit at least 5 years ago.
open label trial of nissle 1917

Conditions: Urinary Tract Infections

Summary: nissle 1917 is an e. coli based probiotic used in the europe for close to 100 years to treat gastrointestinal disorders and infections. the investigators will assess the safety and tolerability of this medication in americans in a phase 1 trial.

background: nissle 1917 is an e. coli based probiotic that has been successfully used in europe for close to 100 years to treat largely gastrointestinal disorders like inflammatory bowel disease, gastroenteritis, and irritable bowel syndrome. in addition to those disorders, we believe that nissle 1917 is a promising alternative therapy for prevention of urinary tract infections in susceptible individuals. purpose: the phase 1 trial will use nissle 1917 in healthy adult patient volunteers for the first time in the united states. the investigators will track the frequency and incidence of side effects and adverse events. participants: 20 adult (\>21 years of age) healthy volunteers protocol: * participants will enroll in our trial after a review of medical history and physical. * participants will then take 30 day course of nissle 1917 capsules * investigators will telephone participants 1-2 weeks after they have begun the trial to assess for any side effects or adverse events * subjects will also be provided with a diary to record any side effects or adverse events * at the end of 30 days, participants will return to clinic for a follow up visit to discuss any side effects or adverse events experienced during the trial and to return any unused medication * investigators will again telephone all participants 28-35 days following completion of the study drug again to pose a questionnaire aimed at revealing any side effects or adverse events.

Eligibility criteria:
inclusion criteria: * healthy adult volunteer of age 21 years or older exclusion criteria: * any individual with an active urinary tract infection (uti) * any individual with an acute illness within the past 7 days * any individual with neurogenic bladder or with vesicoureteral reflux * any individual with any anatomic abnormality, congenital or acquired, of the urinary tract system * any individual with any anatomic abnormality, congenital or acquired, of the gastrointestinal tract * any individual with untreated dysfunctional elimination syndrome * immunocompromised patients * individuals with a central venous catheter * individuals requiring the use of antibiotics, immunomodulatory medications, or other probiotics * any participant with a history of chronic gastrointestinal disease * any individual with a chronic uncontrolled medical illness * any female of reproductive age who is currently pregnant, breastfeeding, or sexually active and unwilling or unable to use an acceptable method of contraception. * any participant is unable to appropriately take and store medication * any individual enrolled in a clinical trial evaluating another investigational agent in the last 30 days.
4-aminopyridine treatment for nerve injury from radical retro-pubic prostatectomy

Conditions: Prostate Disease

Summary: the purpose of this study is to see if the study drug 4-aminopyridine (4-ap) can help speed up the recovery of peripheral nerve injury after prostatectomy. 4-ap is a potassium channel blocker used to improve walking in multiple sclerosis patients. investigators will measure the effect that 4-ap may have on the recovery of sexual function and urinary incontinence after prostatectomy.


Eligibility criteria:
inclusion criteria * male patients with organ-confined, non-metastatic prostate cancer (stages ct1c-t2c), planning to undergo robotic-assisted laparoscopic bilateral nerve sparing radical prostatectomy (nsrp) * prostate-specific antigen (psa) levels less than 10 ng/ml, with biopsy-proven prostate cancer, for whom postoperative adjuvant therapy (e.g. radiation or androgen deprivation therapy) is not expected to be needed * ages 45-75 * an international index of erectile function-erectile function (iief-5) score of greater than or equal to 17 at time of screening * is sexually active for at least 6 months with sexual activity within 6 weeks preceding prostate biopsy or surgery. * willingness to participate and able to provide informed consent exclusion criteria * planned adjuvant therapy after nsrp based on specimen pathology and stage of prostate cancer (stage t3 or greater), positive lymph nodes or positive surgical margins. * history of prior phosphodiesterase inhibitor use * neo-adjuvant therapy prior to nsrp * history of recurrent prostate cancer * history of seizures, multiple sclerosis, stroke or any other diagnosed neurological disorder * history of non-organ confined or metastatic prostate cancer (clinical stages t3 or greater) * history of known hypersensitivity to ampyra® or 4-aminopyridine * patients with history of penile surgery other than circumcision or endoscopic urethral stricture surgery. * renal impairment based on calculated gfr (gfr\<60 ml/min) * use of any other aminopyridine medications for any other indication
access (access for cancer caregivers for education and support for shared decision making)

Conditions: Cancer; Pain

Summary: the project will test the effect of educating and supporting family caregivers of hospice cancer patients on their active participation in shared decision making in the plan of care for their patients.

this intervention will target education and emotional support to family caregivers of hospice cancer patients for a shared decision making process in the hospice care plan meetings the intervention access will consist of three components: 1: a facebook group to provide the education and support; 2. web conferencing for family members into the hospice interdisciplinary care plan meeting 3, a structured shared decision making process to guide the team discussion. participants (family caregivers) will be randomly assigned to one of three groups, usual care, facebook only, and access. the specific aims are to: 1. evaluate the effect of access on family caregiver anxiety, pain knowledge and patient pain. 2. evaluate the effect of facebook groups as educational emotional support for family caregivers 3. assess staff and family caregiver satisfaction with the shared decision making process.

Eligibility criteria:
inclusion criteria: * is caregiving for a patient enrolled in the participating hospice * over 18 years of age * is caregiving for a patient with a diagnosis of cancer * willing to have a facebook account and post at least 1x per week if in intervention group exclusion criteria: * no one under the age of 18 * is caregiving for a patient enrolled in hospice agencies other than those participating in the study * unwilling to participate in social media * is caregiving for a patient with a diagnosis other than cancer * is caregiving for a patient with a life expectancy of less than 2 weeks

Keywords: hospice caregiver
batiraxcept (avb-s6-500)/placebo in combination with paclitaxel in patients with platinum-resistant recurrent ovarian cancer

Conditions: Platinum-resistant Ovarian Cancer

Summary: this is a randomized, double-blind phase 3 study to compare the efficacy and safety of batiraxcept (avb-s6-500) in combination with paclitaxel (pac) versus placebo in combination with pac in patients with platinum resistant recurrent ovarian cancer.


Eligibility criteria:
inclusion criteria: * histologically confirmed and documented recurrent ovarian, fallopian tube, or peritoneal cancer. only patients with high-grade serous adenocarcinoma histology are eligible. * aged 18 years or older * eastern cooperative oncology group performance status (ecog-ps) of 0 to 1 * platinum-resistant disease (defined as progression within ≤6 months from completion of most recent platinum-containing regimen and calculated from the date of the last administered dose of platinum therapy).subject may have been treated with additional regimen(s) subsequent to determination of platinum resistance. * available archived tumor tissue or if archived tissue is not available, a fresh tumor biopsy. * received at least 1 but not more than 4 prior therapy regimens. note: maintenance therapy or hormonal therapies should not be counted as a separate therapy. note: patients who have not received prior bevacizumab must be deemed medically inappropriate or ineligible to receive bevacizumab, refused to receive bevacizumab, or been unable to receive bevacizumab due to lack of access. * measurable disease according to recist v1.1 criteria * normal gastrointestinal function. * at least 28 days between termination of prior anticancer or hormonal therapy and first administration of batiraxcept. * full recovery from all treatment-related toxicities to grade 1 or less, except alopecia. exclusion criteria: * tumors in the breast or bone * untreated central nervous system (cns) metastases. subjects requiring corticosteroid therapy for the management of their treated cns metastases may not be on \>10 mg/day prednisone or equivalent or have demonstrated signs or symptoms of neurologic instability for 28 days or less prior to randomization. * primary platinum-refractory disease (defined as progression during or within 4 weeks after completion of the first platinum regimen) * is being treated with concurrent anticancer therapy or other interventional treatments administered for their underlying ovarian cancer. * received prior therapy with pac in the platinum-resistant recurrent setting * evidence of clinically significant third spacing (e.g., pleural effusions, ascites, anasarca, etc.) that requires therapeutic intervention within 28 days prior to first dose of batiraxcept/placebo

Keywords: ovarian cancer platinum resistant recurrent ovarian cancer high-grade serous adenocarcinoma
hiv and multi-drug resistant tuberculosis: a study on clinical outcomes

Conditions: HIV Infection; MDR-TB

Summary: this study aims to investigate the relationship between hiv infection and multi-drug resistant tuberculosis (mdr-tb) among affected individuals in zahedan, iran. it will involve a detailed analysis of patient demographics, clinical characteristics, and treatment outcomes to enhance understanding of this co-infection. the findings may inform better treatment strategies and healthcare policies for managing these diseases in similar populations.


Eligibility criteria:
inclusion criteria: * adults (aged 18 years and older) diagnosed with both hiv and multi-drug-resistant tuberculosis (mdr-tb). * studies published in peer-reviewed journals. * studies that provide data on the co-occurrence of hiv and mdr-tb. * participants from diverse geographical regions to enhance generalizability. * studies with clear definitions of mdr-tb according to who guidelines. exclusion criteria: * studies that focus solely on drug-susceptible tuberculosis without mdr-tb. * studies involving pediatric populations (under 18 years of age). * non-original research such as reviews, editorials, and commentaries. * studies lacking sufficient data on the co-occurrence of hiv and mdr-tb. * studies that do not adhere to ethical guidelines for human subjects or lack appropriate ethical approvals.
a double blinded study to examine the effect of coated suppositories on fecal incontinence in patients with spinal cord injury

Conditions: Fecal Incontinenece

Summary: this is a double blinded cross over study. approximately 20 spinal cord injury patients will be participating in this 4 weeks study.the primary outcome is difference in fecal incontinence as recorded in diaries, between the treatment period and the treatment period.


Eligibility criteria:
inclusion criteria: signed written informed consent; male or female subjects 18 to 55 years of age; spinal cord lesion/disease/injury at any level at least 3 months from injury. fisi (fecal incontinence severity index) \> 8 units. the patient is able to understand the treatment and is willing to comply with the prescribed regimen exclusion criteria: * known allergy to experimental drug.. * porphiria. * glaucoma. * pregnancy or lactation. * active or past history of cardiovascular or cerebrovascular disease including unstable angina, myocardial infarction, transient ischemic attacks/stroke, clinically significant arrhythmia, congestive heart failure, or cardiac valve abnormalities; * type 1 diabetes mellitus; * insulin treated type 2 diabetes mellitus. * renal insufficiency. * liver insufficiency. * malignant disease within 5 years of screening; * has hypertension (sitting blood pressure \> 140/90 mmhg at screening) * history of rectal surgery. * history of hiv, hepatitis b, hepatitis. * has used, in the last four weeks, drugs that may affect blood coagulation, such as aspirin (at a dose above 250 mg/day), warfarin, sintrom, enoxaparin, nadroparin, heparin, clopidogrel, ticlopidine. * use of tricyclic or monoamine-oxidase inhibors. * has upon physical examination a rectal deformation or signs of rectal disease such as fissure, bleeding hemorrhoids, fistula, infection or space occupying lesion. * unable to understand the use instruction for the coated suppository, as judged by the investigator.
characterization of children with complaints of excessive daytime sleepiness

Conditions: Excessive Daytime Sleepiness

Summary: 10% of the population suffers from excessive daytime sleepiness. this can be explained by a variety of etiologies: psychiatric disorders, altered sleep quantity or quality, hypersomnia... the consequences on quality of life are not negligible, with emotional, academic, social, financial and somatic repercussions. diagnosing and managing them is essential. this is the role of the hfme's child sleep service, a reference center for rare narcolepsy and hypersomnia, which carries out a weekly hypersomnia assessment. in this context, the investigators are carrying out a retrospective descriptive study, the primary objective of which is to describe the results and diagnoses of hypersomnia check-ups in the hfme's sleep department, in order to obtain feedback on the center's activity and its evolution. the secondary objectives are to characterize the patients in the different diagnostic groups, to highlight factors associated with the different diagnoses, and to describe changes in patient characteristics over time.


Eligibility criteria:
inclusion criteria: * - patient hospitalized in the hfme sleep department for a "diagnostic assessment of hypersomnia". * age under 18 at the time of hospitalization * from january 2015 to december 2023 exclusion criteria: * - no balance sheet * age over 18 at time of hospitalization * assessment for medicolegal or therapeutic adaptation purposes
inflammatory responses to lipid emulsions in children before and after open heart surgery

Conditions: Inflammation; Cardiac Surgical Procedures

Summary: this study is a blinded, randomized, controlled prospective trial comparing immune response (sepsis, inflammatory response, pulmonary vasoconstriction) in 2 groups of infants less than 3-month old receiving pre and post cardiopulmonary bypass surgery. the infants will receive 1 out of the 2 following intravenous lipid preparations: soybean oil (n-6), or a combination of medium chain triglyceride i.e. coconut oil, long chain triglyceride i.e. soybean oil, and fish oil (mct:lct:fo). there will be 16 subjects in each group.


Eligibility criteria:
inclusion criteria: * 36 weeks gestation * 3 months corrected age * appropriate for gestational age (aga) * admitted for surgical correction of congenital heart defects (single ventricle, tetralogy of fallot, truncus and complex biventricular repairs) * enteral nutrition at 30 kcal/kilogram/day exclusion criteria: * 5 minute apgar score of 4 * major congenital defect other than heart defect * presence of significant neonatal morbidity (intraventricular hemorrhage (ivh) grade 3 or greater, necrotizing enterocolitis (nec) and surgical abdomen) * any metabolic disorder * any endocrine disorder * medications which alter eicosanoid metabolism including indomethacin, acetylsalicylate (with exception of steroids which will be analyzed independently)

Keywords: intensive care,neonatal parenteral nutrition fat emulsions,intravenous
intervention study of depression in breast cancer patients

Conditions: Breast Cancer; Depression; Anxiety

Summary: the purpose of this study is to evaluate the efficacy of cognitive-behavioral therapy on depression and anxiety in breast cancer patients.

comprehensive intervention on depression and anxiety in breast cancer patients is a 24-week, multicenter, randomized, blinded controlled clinical study, which uses cognitive-behavioral therapy. this study tries to evaluate the efficacy of sequential therapy on breast cancer patients' depression and its improvement on breast cancer patients' life quality, pain and sleeping.

Eligibility criteria:
inclusion criteria: * age: 20-65 years; * pathologically diagnosed breast cancer patients, with the diagnosis from at least 2 comprehensive clinical attending physicians, in line with clinical diagnosis of breast cancer; * a week after breast cancer surgery; * with complaints and symptoms of depression or anxiety * hamd-17 ≥ 8 points or / and hama ≥ 8 points; * have some reading comprehension skills (could complete the self-rating scale independently or with others' help); * informed consent exclusion criteria: * previous diagnosis of mental disorder or bipolar disorder; alcohol and drug abusing history; * use antidepressants, antipsychotics or accept any form of psychological treatment, or participation in other clinical trials in the last month * patients with cardiovascular disease, liver and kidney dysfunction and other serious diseases; * hearing, visual or understanding impairment; * severe depression, suicidal tendencies; * can not or will not comply with clinical treatment programs based on the physicians' judgment exit criteria: * persons with poor compliance during the trial period; * persons whose depression increased during the trial period, has serious suicidal tendencies and requires urgent intervention; * persons who are believed have other circumstances and should be suspended by physicians

Keywords: breast cancer depression anxiety cognitive-behavioral therapy
effects of modified constraint-induced on chronic stroke patients

Conditions: Stroke; Rehabilitation

Summary: in the present study, it was aimed to compare the proprioception training applied in addition to conventional treatment and modified constraint-induced movement therapy treatment in patients with chronic strokes and to investigate the effects on proprioception, spasticity, functional motor skills and daily living activities in the upper extremity.


Eligibility criteria:
inclusion criteria: * post stroke hemiparetic patients of six months * spasticity ≤ grade -3 on modified ashworth scale * those patients capable of extension of at least 10º each at metacarpophalangeal (mcp), proximal interphalangeal (pip) and distal interphalangeal (dip) joints and 20º at wrist joint * a score of 24 or higher on the modified mini-mental state examination * no excessive pain in the affected upper limb, as measured by a score of 4 or higher on a 10-point visual analog scale exclusion criteria: * patients with history of previous stroke, * angina, * uncontrolled hypertension, on medication that could impair neuromuscular performance, * wrist or finger pathologies, significant visual or hearing impairment, * balance problems which may compromise safety during sound upper limb constraint, * unwilling to participate

Keywords: modified constraint-induced therapy proprioceptive training conventional rehabilitation